Limits...
Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration.

Rotsos T, Patel PJ, Chen FK, Tufail A - Clin Ophthalmol (2010)

Bottom Line: Visual acuity outcomes and adverse events were noted, as were service delivery-related indicators.The mean (median) number of injections was 4.7 (4.5) per 12-month period.The mean (median) delay in Primary Care Trust funding approval was 35 days (32 days) prior to the final appraisal document from the National Institute of Health and Clinical Excellence.

View Article: PubMed Central - PubMed

Affiliation: Medical Retina Service, Moorfields Eye Hospital, London, UK. tryfonrotsos@hotmail.com

ABSTRACT

Purpose: To describe the visual acuity and safety outcomes for the first 50 patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab at Moorfields Eye Hospital.

Methods: A retrospective analysis of case notes from the first 50 consecutive patients with Primary Care Trust funding for ranibizumab therapy for nAMD. Visual acuity outcomes and adverse events were noted, as were service delivery-related indicators.

Results: The mean (±standard deviation) age of the 50 patients was 81 ± 17 years. The mean follow-up of patients was 13.6 ± 2 (range 7.7-18) months. The mean change in visual acuity ± standard error was +4.6 ± 2.2 letters at the end of follow-up, with 26% gaining 15 letters or more. The mean (median) number of injections was 4.7 (4.5) per 12-month period. The mean (median) delay in Primary Care Trust funding approval was 35 days (32 days) prior to the final appraisal document from the National Institute of Health and Clinical Excellence.

Conclusions: The real-world outcomes of ranibizumab therapy in this initial cohort of patients with nAMD are comparable with those reported in the pivotal, randomized, controlled trials using fewer injections and a prn strategy of retreatment to achieve the gain in visual acuity.

No MeSH data available.


Related in: MedlinePlus

Plot of change in visual acuity against length of follow-up.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2993128&req=5

f2-opth-4-1271: Plot of change in visual acuity against length of follow-up.

Mentions: No correlation was found between number of injections over 12 months and baseline visual acuity (Pearson, r = 0.06; P = 0.70; Spearman, r = 0.05; P = 0.74). We did not carry out an analysis of the correlation between baseline lesion angiographic subtype and number of treatments because there were too few classic no occult or predominantly classic lesions to permit a meaningful analysis. No correlation was found between number of injections over 12 months and change in visual acuity at final follow-up (Pearson, r = 0.18; P = 0.21; Spearman, r = 0.06; P = 0.70). In addition, as Figure 2 demonstrates, no correlation was found between change in visual acuity and length of follow-up (Pearson, r = 0.17; P = 0.25; Spearman, r = 0.09; P = 0.54).


Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration.

Rotsos T, Patel PJ, Chen FK, Tufail A - Clin Ophthalmol (2010)

Plot of change in visual acuity against length of follow-up.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2993128&req=5

f2-opth-4-1271: Plot of change in visual acuity against length of follow-up.
Mentions: No correlation was found between number of injections over 12 months and baseline visual acuity (Pearson, r = 0.06; P = 0.70; Spearman, r = 0.05; P = 0.74). We did not carry out an analysis of the correlation between baseline lesion angiographic subtype and number of treatments because there were too few classic no occult or predominantly classic lesions to permit a meaningful analysis. No correlation was found between number of injections over 12 months and change in visual acuity at final follow-up (Pearson, r = 0.18; P = 0.21; Spearman, r = 0.06; P = 0.70). In addition, as Figure 2 demonstrates, no correlation was found between change in visual acuity and length of follow-up (Pearson, r = 0.17; P = 0.25; Spearman, r = 0.09; P = 0.54).

Bottom Line: Visual acuity outcomes and adverse events were noted, as were service delivery-related indicators.The mean (median) number of injections was 4.7 (4.5) per 12-month period.The mean (median) delay in Primary Care Trust funding approval was 35 days (32 days) prior to the final appraisal document from the National Institute of Health and Clinical Excellence.

View Article: PubMed Central - PubMed

Affiliation: Medical Retina Service, Moorfields Eye Hospital, London, UK. tryfonrotsos@hotmail.com

ABSTRACT

Purpose: To describe the visual acuity and safety outcomes for the first 50 patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab at Moorfields Eye Hospital.

Methods: A retrospective analysis of case notes from the first 50 consecutive patients with Primary Care Trust funding for ranibizumab therapy for nAMD. Visual acuity outcomes and adverse events were noted, as were service delivery-related indicators.

Results: The mean (±standard deviation) age of the 50 patients was 81 ± 17 years. The mean follow-up of patients was 13.6 ± 2 (range 7.7-18) months. The mean change in visual acuity ± standard error was +4.6 ± 2.2 letters at the end of follow-up, with 26% gaining 15 letters or more. The mean (median) number of injections was 4.7 (4.5) per 12-month period. The mean (median) delay in Primary Care Trust funding approval was 35 days (32 days) prior to the final appraisal document from the National Institute of Health and Clinical Excellence.

Conclusions: The real-world outcomes of ranibizumab therapy in this initial cohort of patients with nAMD are comparable with those reported in the pivotal, randomized, controlled trials using fewer injections and a prn strategy of retreatment to achieve the gain in visual acuity.

No MeSH data available.


Related in: MedlinePlus